Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the t…
| Periodo | 2022-12 | 2022-05 |
|---|---|---|
| Real | $-0.06 | $-0.06 |
| Estimado | — | $-0.06 |
| Sorpresa | — | +0.0% |
| Métrica | TLSA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -301.4% | -39.2% | -262.2% |
| ROA | -105.1% | -30.9% | -74.2% |
| Current Ratio | 1.02 | 2.73 | -1.71 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -105.1% | — |
| ✗Flujo de caja operativo positivo | −$2M | −$16M |
| ✓Rentabilidad sobre activos al alza | -105.1% | -145.2% |
| ✓Caja operativa/activos supera al ROA | -13.5% | ROA -105.1% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.02 | 1.12 |
| ✗Sin aumentar el nº de acciones | 107M | 102M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY24 |
|---|---|
| ✗ROCE > 10 % | -401.3% |
Tiziana Life Sciences Ltd cotiza a 1.05 USD y tiene una capitalización bursátil de $134M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud